World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
52606
World Ranking
9482
National Ranking
4892

Overview

Maha Hussain is affiliated with Northwestern University in the United States and has contributed extensively to the field of medicine, with a focus on oncology and cancer research. Their publication record spans several subfields, including pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and molecular biology.

Their research topics predominantly cover prostate cancer treatment and research, cancer, lipids, and metabolism, radiopharmaceutical chemistry and applications, prostate cancer diagnosis and treatment, PARP inhibition in cancer therapy, cancer treatment and pharmacology, as well as hormonal and reproductive studies.

Recent published works highlight their involvement in significant clinical and translational cancer research. These include:

  • ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, 2021, Nature
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, 2020, New England Journal of Medicine
  • Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection, 2022, JAMA Pediatrics

Frequent coauthors with significant collaboration counts include:

  • Fred Saad
  • Karim Fizazi
  • Bertrand Tombal
  • Cora N. Sternberg
  • Neal D. Shore

Hussain regularly publishes in a selection of medical journals, with major contributions in:

  • Journal of Clinical Oncology
  • European Urology
  • Annals of Oncology
  • The Journal of Urology
  • bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer

    Maha Hussain;Karim Fizazi;Fred Saad;Per Rathenborg

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

  • Identification of Targetable FGFR Gene Fusions in Diverse Cancers

    Yi Mi Wu;Fengyun Su;Shanker Kalyana-Sundaram;Nickolay Khazanov

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

  • Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group

    Michael K. Gibson;Yi Li;Barbara Murphy;Maha H.A. Hussain

  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

    Maha Hussain;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    David C. Smith;Matthew R. Smith;Christopher Sweeney;Aymen A. Elfiky

  • Erratum: Integrative Clinical Genomics of Advanced Prostate Cancer

    Dan Robinson;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

    J. Chad Brenner;Bushra Ateeq;Yong Li;Anastasia K. Yocum

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

  • Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)

    Maha Hussain;Catherine M. Tangen;Celestia Higano;Paul F. Schelhammer

Frequent Co-Authors

Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Catherine M. Tangen
Catherine M. Tangen Fred Hutchinson Cancer Research Center
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio
Celestia S. Higano
Celestia S. Higano University of Washington
Fred Saad
Fred Saad University of Montreal
Cora N. Sternberg
Cora N. Sternberg Cornell University
David I. Quinn
David I. Quinn University of Southern California
Michael A. Carducci
Michael A. Carducci Johns Hopkins University
E. David Crawford
E. David Crawford University of California, San Diego
Karim Fizazi
Karim Fizazi University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always start at medical school. Many students consider alternative healthcare degrees to build a foundation or expand their opportunities. For those looking to enter the healthcare field, online nursing programs offer a flexible and cost-effective way to gain essential skills while balancing work or family commitments.

Advancing your nursing credentials can also be affordable. If you’re a registered nurse seeking to further your education, you can find cheap rn to bsn online programs designed to transition into advanced roles.

For those considering research or academic careers, pursuing one of the cheapest phd nursing programs can open doors to professorships or leadership in healthcare policy. These advanced degrees can be completed online and are often more affordable than traditional options.

Additionally, non-nursing majors can quickly pivot into the nursing field by enrolling in direct entry msn programs for non-nursing majors online. These programs provide a fast-track option, ideal for career changers or those seeking a streamlined path to advanced nursing practice.

Best Scientists Citing Maha Hussain

Trending Scientists